Section Arrow
Quote
IMCR.NASDAQ
- Immunocore Holdings plc
Quotes are at least 15-min delayed:2026/06/06 18:41 EDT
Regular Hours
Last
 28.29
-0.47 (-1.63%)
Day High 
29.1 
Prev. Close
28.76 
1-M High
31.48 
Volume 
282.09K 
Bid
27.5
Ask
28.81
Day Low
27.6668 
Open
28.76 
1-M Low
27.82 
Market Cap 
1.46B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 29.07 
20-SMA 29.08 
50-SMA 29.75 
52-W High 40.7147 
52-W Low 27.555 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.56/1.57
Enterprise Value
1.90B
Balance Sheet
Book Value Per Share
7.74
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
310.20M
Operating Revenue Per Share
4.60
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
BCDABioCardia Inc.1.03+0.111+12.08%-- 
BGMSBio Green Med Solution Inc1.5+0.44+41.51%0.3PE
CMNDClearmind Medicine Inc.3.98+1.07+36.77%-- 
ADTXAditxt Inc.0.0621-0.0149-19.35%-- 
RXRXRecursion Pharmaceuticals3.315-0.485-12.76%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.